Company Dashboard

Get the latest news, press releases, earnings, outlook, ratings, and dividends for any company.

Syndax Pharmaceuticals, Inc. ( NASDAQ : SNDX )

Sector: Healthcare | Industry: Biotechnology

Pre-Market	Intra-Day	After-Hours
—	13.53 ( -0.42 / -3.01% )	—
—	14-Oct 16:00	13-Oct 19:00

Previous Close	13.95	52-Week Low	12.99
Open	13.87	52-Week High	25.59
Day Low	13.40	50-Day Average	18.85
Day High	14.01	200-Day Average	20.72
Volume	3.01 M	Market Cap	1.2 B

Stock News

Chart

Press Releases

Analysis

Earnings

Outlooks

Ratings

Dividends

Upcoming Catalysts

SNDX Stock News

Latest 5 Stock News records for SNDX from CatalystPICR and external news sources.

Showing 1 – 5 of 5 news items for SNDX from 2026-10-12 to 2026-10-14

14-Oct-2026

10:56

SNDX

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal

Zacks Investment Research

SNDX shares plunge 16% as its phase II axatilimab study misses the primary endpoint, prompting the company to abandon development in idiopathic pulmonary fibrosis.

13-Oct-2026

23:00

SNDX

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)

GuruFocus

Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)PR NewswireNEW YORK, Oct. 13, 2026SNDX shareholders saw the

13-Oct-2026

12:24

SNDX

Syndax Pharmaceuticals Suffers Pipeline Blow

Benzinga

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) announced it will halt the clinical development of axatilimab in idiopathic pulmonary fibrosis (IPF) after the drug missed its primary endpoint in the Phase 2 MAXPIRe trial.

13-Oct-2026

08:02

SNDX

Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

Benzinga

U.S. stock futures were mixed this morning, with the Dow futures gaining around 200 points on Tuesday. Shares of Syndax Pharmaceuticals, Inc (NASDAQ:SNDX) fell sharply in pre-market trading after the company announced that the MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint of the annualized rate of decline in forced vital capacity.

12-Oct-2026

17:00

SNDX

Syndax Pharmaceuticals (SNDX) Phase 2 Trial Misses Endpoint

Catalyst PICR

Syndax Pharmaceuticals (SNDX) announced that its Phase 2 trial of axatilimab for idiopathic pulmonary fibrosis did not meet its primary endpoint. The company will not continue developing axatilimab for this condition, although ongoing trials for other indications will proceed. Axatilimab is FDA approved for chronic graft-versus-host disease and showed a consistent safety profile in the trial.